BioSupply Trends Quarterly logo
Search
Close this search box.

FDA Approves Wezlana, First Interchangeable Biosimilar to Stelara

FDA Approves Wezlana, First Interchangable Biosimilar to Stelara

The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis; moderately to severely active Crohn’s disease; and moderately to severely active ulcerative colitis.

FDA Approves Humira Biosimilar to Treat Autoimmune Disorders

psoriatic arthritis autoimmune disorder

The U.S. Food and Drug Administration has approved Samsung Bioepis; Halima (adalimumab-bwwd) for the treatment of several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.